Close

Anti-C50H99NO9 T cell receptor (Vα14Vβ7), pCDTCR1 (TCR-YC0266)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

NKT cells are traditionally categorized into two distinct populations: type I and type II. Type I NKT cells express an invariant α-chain variable region 14–α-chain joining region 18 (Vα14-Jα18; TRAV11-TRAJ18) TCR α-chain in mice or Vα24-Jα18 (TRAV10-TRAJ18) in humans and can recognize the prototypical glycolipid antigen α-galactosylceramide (α-GalCer). Type II NKT cells are also CD1d restricted but do not express this invariant TCR α-chain or recognize α-GalCer.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • C50H99NO9
  • Target Species
  • Agelas mauritiana
  • Epitope
  • 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine
  • Format
  • Non-Modified TCR
  • Allele
  • mouse CD1d
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • Vα14Vβ7
  • Host Species
  • Mouse

Target

  • Introduction
  • A glycophytoceramide having an α-D-galactosyl residue at the O-1 position and a hexacosanoyl group attached to the nitrogen.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Mouse anti-C50H99NO9 T cell receptor (Vα14Vβ7), pCDTCR1 (TCR-YC0266). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.